Trinity Capital announced the commitment of $30 million in growth capital to Elucent Medical ("Elucent"), a pioneering medical technology company transforming the field of guided surgical technologies.

Elucent amplifies the field of surgical guidance, transforming standard instruments into smart tools with In-Body Spatial Intelligence™, giving physicians true 3D surgical awareness for unmatched precision.  Based in Eden Prairie, Minnesota, Elucent developed the EnVisio® System, which uses a spatial field generator measuring continuous data points across multiple planes, to display exact 3D positioning of the SmartClip® marker and SmartSensor™ used to guide soft-tissue surgical excision. EnVisio's adaptive design and seamless integration redefine surgical precision, enabling an intuitive, uninterrupted experience that enhances precision and accuracy for better outcomes.   

"Elucent is disrupting the field of surgical guidance with its cutting-edge technology," said Lauren Cosentino, Managing Director, Life Sciences at Trinity Capital. "We are thrilled to be a part of Elucent's journey as they continue to innovate and improve surgical outcomes."

"Our EnVisio® System gives surgeons confidence before, during, and after their surgical procedures so they know they have delivered unparalleled accuracy and precision for their patients. We are in scale mode and are excited to partner with Trinity Capital," said Jason Pesterfield, CEO at Elucent. Trinity Capital's investment will be key to our continued acceleration of our innovation and commercialization efforts."

Earlier in 2024, Elucent raised $44.0 million in its Series C funding round. This additional growth capital will be used to scale operations.